Dear Friends of Bexion
HAPPY NEW YEAR!
PHASE I CLINICAL TRIAL UPDATE
Currently Bexion is in the Phase Ib expansion portion of our Phase I Clinical Trial, where solid tumor patients are receiving the maximum planned dose of BXQ-350. We are anticipating closing our Phase I trial within the next 6 months. Due to the enthusiasm of the physicians leading our clinical trial in recruiting patients, we are over a year ahead of schedule.
To date, there have been no serious adverse events attributed to BXQ-350. The first patient, a Glioblastoma Multiforme (GBM) male is the longest duration on the study; now >16 months.
Depending on the outcome of several patients currently on study, over the next few months Bexion is examining the potential of a Pediatric Rare Disease Designation.
AN EXCITING YEAR AHEAD!
Bexion has scheduled multiple batches of BXQ-350 to be manufactured in 2018. Each batch takes approximately 6-10 months to produce final drug and an investment of over $1MM. Bexion plans to produce sufficient BXQ-350 to support our Pediatric Phase Ia trial, a potential combination therapy trial and the beginning of more advanced trials.
Several clinical trials are being planned for 2018.
- Pediatric Phase Ia Clinical Trial for Solid Tumors
- Adult Phase I Clinical Trial using BXQ-350 in Combination
- Adult Advanced Clinical Trial (GBM or Rare Disease)
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)
For the first time Bexion is submitting a clinical scientific abstract highlighting findings from our Phase Ia Trial in the Trials in Progress category for the ASCO Annual Meeting held in Chicago in June. Founded in 1964, ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. The Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Trials in Progress posters provide an opportunity for Bexion to present ongoing trials, foster collaboration, and discuss novel trial designs. In addition, Trials in Progress provides “coming attractions” for oncologists in clinical practice and potential investors. Acceptance to present will be Bexion’s debut at this prestigious meeting.
In November 2017 Bexion opened a Series B Preferred Stock Financing to raise $10MM. This round will support manufacture of BXQ-350 and the planning and initiation of several clinical trials. Existing Investors and a new investor have already committed $3.7MM of the $10MM to be raised.
This newsletter contains forward-looking statements that are current at the time of release. The company’s plans may change depending on, for example, clinical results, drug availability, and finances.